Everest Medicines , a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that the findings of reduction in proteinuria and stabilization of eGFR in a Chinese subpopulation after 9 months of treatment with NEFECON are in line with topline results from Part A of the pivotal global Phase 3 clinical trial NefIgArd, which were reported in November 2020 by Calliditas Therapeutics AB.

Everest Medicines secured exclusive license rights from Calliditas Therapeutics AB in 2019 to develop and commercialize NEFECON for the treatment of primary IgA nephropathy (IgAN) in Greater China and Singapore, which territory was expanded to include South Korea in March of this year.

In November 2020, Calliditas reported that topline results from Part A of the global trial provided evidence of a statistically significant reduction in proteinuria, after 9 months of treatment.  The trial also met the key secondary endpoint showing a statistically significant difference in estimated glomerular filtration rate or eGFR after 9 months of treatment compared to placebo.  NEFECON was generally well-tolerated.